OSUR OraSure Technologies Inc.

OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference

OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference

BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Raymond James 42nd Annual Institutional Investors Conference. The conference will be simultaneously webcast over the Internet.

Dr. Tang is scheduled to speak on March 3, 2021, at approximately 10:00 AM Eastern Standard Time (7:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site,  and clicking on the Investor Relations link. A replay of the webcast will be available on OraSure Technologies’ web site for 14 days. Alternatively, you can access the live webcast of the presentation via the following link: .

About OraSure Technologies

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit .

Company contacts:

Sam Martin

Argot Partners

212-600-1902

Jeanne Mell

VP Corporate Communications

484-353-1575





EN
24/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

 PRESS RELEASE

OraSure Launches Novel Blood Collection Device for Proteomic Research

OraSure Launches Novel Blood Collection Device for Proteomic Research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research BETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed by OTI subsidiary DNA Genotek, is an evacuated blood colle...

 PRESS RELEASE

OraSure Announces First Quarter 2025 Financial Results

OraSure Announces First Quarter 2025 Financial Results BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. “Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some ...

 PRESS RELEASE

OraSure to Announce First Quarter 2025 Financial Results and Host Earn...

OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will b...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OraSure Announces $40 Million Stock Repurchase Program

OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. The amount and timing of sha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch